These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12125971)

  • 1. PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade.
    Kayaselçuk F; Zorludemir S; Gümürdühü D; Zeren H; Erman T
    J Neurooncol; 2002 Apr; 57(2):115-21. PubMed ID: 12125971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material.
    Karamitopoulou E; Perentes E; Diamantis I; Maraziotis T
    Acta Neuropathol; 1994; 87(1):47-54. PubMed ID: 7511316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferating cell nuclear antigen (PCNA) and Ki-67 immunopositivity in human astrocytic tumours.
    Kordek R; Biernat W; Alwasiak J; Liberski PP
    Acta Neurochir (Wien); 1996; 138(5):509-12; discussion 513. PubMed ID: 8800324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67.
    Deckert M; Reifenberger G; Wechsler W
    J Cancer Res Clin Oncol; 1989; 115(2):179-88. PubMed ID: 2715168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry.
    Møller ML; Braendstrup O
    J Neurooncol; 1997 Sep; 34(3):241-6. PubMed ID: 9258816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
    Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens.
    Khoshyomn S; Maier H; Morimura T; Kitz K; Budka H
    Acta Neuropathol; 1993; 86(6):582-9. PubMed ID: 7906072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome.
    Kayaselçuk F; Zorludemir S; Bal N; Erdogan B; Erdogan S; Erman T
    J Neurooncol; 2004; 67(1-2):209-14. PubMed ID: 15072469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors.
    Bodey B; Bodey B; Gröger AM; Siegel SE; Kaiser HE
    Anticancer Res; 1997; 17(1A):189-96. PubMed ID: 9066650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of p53-protein expression and the PCNA and Ki-67 proliferating cell indices in human astrocytomas.
    Kordek R; Biernat W; Debiec-Rychter M; Alwasiak J; Liberski PP
    Pathol Res Pract; 1996 Mar; 192(3):205-9. PubMed ID: 8739466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study.
    Takeuchi H; Kubota T; Kabuto M; Kitai R; Nozaki J; Yamashita J
    Surg Neurol; 1997 Nov; 48(5):501-6. PubMed ID: 9352816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time.
    Schröder R; Bien K; Kott R; Meyers I; Vössing R
    Acta Neuropathol; 1991; 82(5):389-94. PubMed ID: 1767633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of PCNA, Ki67, AgNOR and p53 expression in brain glial tumors].
    Berny W; Weiser A; Markowska-Woyciechowska A; Jarmundowicz W; Zub W; Załuski R
    Neurol Neurochir Pol; 2004; 38(6):457-63. PubMed ID: 15654669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain tumor invasion rate measured in vitro does not correlate with Ki-67 expression.
    Khoshyomn S; Lew S; DeMattia J; Singer EB; Penar PL
    J Neurooncol; 1999; 45(2):111-6. PubMed ID: 10778726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study.
    Louis DN; Edgerton S; Thor AD; Hedley-Whyte ET
    Acta Neuropathol; 1991; 81(6):675-9. PubMed ID: 1679278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of thallium-201 uptake with proliferating cell nuclear antigen in brain tumours.
    Gungor F; Bezircioglu H; Guvenç G; Tezcan M; Yildiz A; Uluc E; Isisag A
    Nucl Med Commun; 2000 Sep; 21(9):803-10. PubMed ID: 11065152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of tumor proliferation marker ki-67 and PCNA in surgical pathology].
    Su J; Zheng J
    Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):568-71. PubMed ID: 20021977
    [No Abstract]   [Full Text] [Related]  

  • 18. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma.
    Cobb MA; Husain M; Andersen BJ; al-Mefty O
    J Neurosurg; 1996 Jan; 84(1):85-90. PubMed ID: 8613841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
    Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
    Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms.
    Prayson RA
    Adv Anat Pathol; 2005 May; 12(3):144-8. PubMed ID: 15900115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.